Most recently, EphA2‐targeted CAR‐modified primary NK cells have demonstrated efficacy against preclinical models of EphA2 antigen‐positive head and neck squamous cell carcinoma (HNSCC),47 which highlights the applicability of EphA2‐targeting CAR‐modified NK cells for sarcoma immunotherapy. This evidence concerns the gene EPHA2 and sarcoma.